GLYC
GlycoMimetics, Inc.

Market cap $825.48M
Enterprise value $745.92M
Employees 42
Revenue $0.00
EBITDA -$32.5M
Income -$32.4M
Book/Share 3.32
Price/Book 7.25
Cash/Share 3.29
Price/Sales 26,375.14
Debt/Equity N/A
EPS -1.22
P/E N/A
Forward P/E -27.95
EV/EBITDA -22.94
PEG N/A
Earnings date 2017-08-03
Volume 498k / 724k
Relative vol. 0.69 ×
Sales Q/Q -100.00%
Sales Y/Y -33.17%
Est. EPS Q/Q N/A
Beta 3.44
Mean Recomm. 1.60
IPO year 2014
Country United States
RSI 57.43
Range $23.71 – $26.00
52 weeks $3.82 – $26.05
SMA 50 $22 -12.93%
SMA 200 $15 -40.01%
1 year target $25 -2.08%

Intraday

5 days

1 month

3 months

6 months

1 year

5 years

10 years

All time

Date
#
Company
Insider Title
Trans.
Transaction
Shares Price per share Total price Shares after Source
2017-05-19 Helen M. Thackray
VP Clinical Development, CMO
VP Clinical Development, CMO Sale 2,000 $12.14 $24,280
2017-05-19
154,615
2017-05-10 John L. Magnani
VP of Research, CSO
VP of Research, CSO Option exercise 8,928 $1.12 $9,999
2017-05-10
99,302
2016-12-20 Daniel M Junius
Director
Director Buy 5,000 $6.01 $30,050
2016-12-20
5,000
2016-10-03 Helen M. Thackray
VP Clinical Development, CMO
VP Clinical Development, CMO Sale 4,000 $7.00 $28,000
2016-10-03
156,615
2016-07-20 Helen M. Thackray
VP Clinical Development, CMO
VP Clinical Development, CMO Sale 2,000 $8.00 $16,000
2016-07-20
160,615
2016-07-01 Helen M. Thackray
VP Clinical Development, CMO
VP Clinical Development, CMO Sale 22,000 $7.00 $154,000
2016-07-01
162,615
2016-06-29 John J. Baldwin
Director
Director Option exercise 605 $1.12 $678
2016-06-29
1,210
2016-03-04 Mark Alan Goldberg
Director
Director Buy 10,397 $4.77 $49,594
2016-03-04
11,497
2016-02-05 Franklin H Jr Top
Director
Director Option exercise 11,689 $1.12 $13,092
2016-02-05
12,294
2015-11-16 Scott D Sandell
10% owner
10% owner Sale 452 $6.91 $3,123
2015-11-16
4,490,751
2015-11-16 Peter J Barris
10% owner
10% owner Sale 452 $6.91 $3,123
2015-11-16
4,490,751
2015-11-16 M James Barrett
Director
Director Sale 452 $6.91 $3,123
2015-11-16
4,490,751
2015-11-16 Enterprise Associates 10 L ...
Sale 452 $6.91 $3,123
2015-11-16
4,490,751

Notable SEC filings of GlycoMimetics, Inc.

Date Contents
Source
2017-08-03 8-K Results of Operations and Financial Condition; Financial Statements and Exhibits
2017-08-03 10-Q Quarterly report
2017-06-12 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Regulation FD Disclosure; Financial Statements and Exhibits
2017-05-25 8-K Entry into a Material Definitive Agreement; Submission of Matters to a Vote of Security Holders; Other Events; Financial Statements and Exhibits
2017-05-24 8-K Termination of a Material Definitive Agreement
2017-05-08 8-K Results of Operations and Financial Condition; Financial Statements and Exhibits
2017-05-08 10-Q Quarterly report
2017-03-13 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Regulation FD Disclosure; Financial Statements and Exhibits
2017-03-01 8-K Results of Operations and Financial Condition; Financial Statements and Exhibits
2017-03-01 10-K Yearly report
2016-11-04 8-K Results of Operations and Financial Condition; Financial Statements and Exhibits
2016-11-04 10-Q Quarterly report
2016-09-23 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
2016-08-04 8-K Results of Operations and Financial Condition; Financial Statements and Exhibits
2016-08-04 10-Q Quarterly report
2016-06-17 8-K Entry into a Material Definitive Agreement; Other Events; Financial Statements and Exhibits
2016-06-10 8-K Regulation FD Disclosure; Financial Statements and Exhibits
2016-06-02 8-K Other Events; Financial Statements and Exhibits
2016-05-18 8-K Submission of Matters to a Vote of Security Holders
2016-05-04 8-K Results of Operations and Financial Condition; Financial Statements and Exhibits
2016-05-04 10-Q Quarterly report
2016-03-29 8-K Entry into a Material Definitive Agreement; Financial Statements and Exhibits
2016-03-21 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Regulation FD Disclosure; Financial Statements and Exhibits
2016-03-01 8-K Entry into a Material Definitive Agreement; Financial Statements and Exhibits
2016-02-29 8-K Results of Operations and Financial Condition; Financial Statements and Exhibits
2016-02-29 10-K Yearly report

GlycoMimetics executives

Insider Title Age Since Compensation
Rachel King (57)
President, Chief Executive Officer, Co-Founder, Director since 2003
President, Chief Executive Officer, Co-Founder, Director 57 2003 $1,233,490
Helen Thackray (47)
Senior Vice President - Clinical Development, Chief Medical Officer since 2017
Senior Vice President - Clinical Development, Chief Medical Officer 47 2017 $809,487
John Magnani (64)
Co-Founder, Senior Vice President, Chief Scientific Officer, Director since 2017
Co-Founder, Senior Vice President, Chief Scientific Officer, Director 64 2017 $761,745
Brian Hahn (42)
Chief Financial Officer since 2012
Chief Financial Officer 42 2012 $670,935
Daniel Junius (64)
Independent Director since 2016
Independent Director 64 2016 $163,976
M. James Barrett (74)
Independent Chairman of the Board since 2017
Independent Chairman of the Board 74 2017 $115,210
Timothy Pearson (49)
Independent Director since 2016
Independent Director 49 2016 $109,210
Mark Goldberg (62)
Independent Director since 2016
Independent Director 62 2016 $90,732
Scott Koenig (64)
Independent Director since 2017
Independent Director 64 2017
Patricia Andrews
Director since 2017
Director 2017
GlycoMimetics, Inc. logo

GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company is developing its lead product candidates include rivipansel, a pan-selectin antagonist, which is in Phase III clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease; and GMI-1271, an E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers. It is also developing GMI-1359, a drug candidate targeting E-selectin and CXCR4; and galectin-3 and galectin-9 inhibitors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.

  • GlycoMimetics, Inc., 9708 Medical Center Drive, Rockville 20850, United States
  • glycomimetics.com
  • 240-243-1201

Quarterly EPS estimates

Profit margin

Debt to assets

Cash flow

Balance sheet

(in millions) 2017Q3 2017Q2 2017Q1 2016Q4
Current assets
Cash $112.872534 $119.147928 $34.590578 $40.041641
Short term investments
Net receivables
Inventory
Other current assets $1.015747 $0.502155 $0.697063 $0.478503
Total current assets $113.888281 $119.650083 $35.287641 $40.520144
Long term investments
Property, plant & equipment $1.122216 $1.159589 $1.074515 $1.056332
Goodwill
Intangible assets
Other assets $0.811851 $0.811851 $0.811851 $0.811851
Deferred long term asset charges
Total assets $115.822348 $121.621523 $37.174007 $42.388327
Current liabilities
Accounts payable $6.456828 $5.37648 $4.463168 $6.265066
Short long term debt
Other current liabilities $0.074072 $0.070598 $0.070598 $0.068551
Total current liabilities $6.5309 $5.447078 $4.533766 $6.333617
Long term debt
Other liabilities
Deferred long term liabilities $0.726986 $0.742584 $0.754055 $0.753579
Minority interest
Total liabilities $7.257886 $6.189662 $5.287821 $7.087196
Stockholders' equity
Stock option warrants
Common stock $0.032736 $0.032715 $0.023854 $0.023249
Retained earnings -$143.019248 -$135.069147 -$126.927351 -$118.976311
Treasury stock
Capital surplus $251.550974 $250.468293 $158.789683 $154.254193
Other stockholder equity
Total stockholder equity $108.564462 $115.431861 $31.886186 $35.301131
Net tangible assets $108.564462 $115.431861 $31.886186 $35.301131
(in millions) 2016 2015 2014
Current assets
Cash $40.041641 $46.80256 $55.198923
Short term investments
Net receivables
Inventory
Other current assets $0.478503 $0.44181 $0.916249
Total current assets $40.520144 $47.24437 $56.115172
Long term investments
Property, plant & equipment $1.056332 $0.521378 $0.45227
Goodwill
Intangible assets
Other assets $0.811851 $0.696531 $0.696531
Deferred long term asset charges
Total assets $42.388327 $48.462279 $57.263973
Current liabilities
Accounts payable $6.265066 $7.746978 $6.363533
Short long term debt
Other current liabilities $0.068551 $0.097012
Total current liabilities $6.333617 $7.746978 $6.460545
Long term debt
Other liabilities
Deferred long term liabilities $0.753579 $0.243647
Minority interest
Total liabilities $7.087196 $7.990625 $6.460545
Stockholders' equity
Stock option warrants
Common stock $0.023249 $0.019049 $0.01894
Retained earnings -$118.976311 -$87.166473 -$74.396975
Treasury stock
Capital surplus $154.254193 $127.619078 $125.181463
Other stockholder equity
Total stockholder equity $35.301131 $40.471654 $50.803428
Net tangible assets $35.301131 $40.471654 $50.803428

Income statement

(in millions) 2017Q3 2017Q2 2017Q1 2016Q4
Revenue
Total revenue
Cost of revenue
Gross profit
Operating expenses
Research & development $5.779759 $5.72207 $5.878508 $6.06046
Selling, general & administrative $2.401976 $2.521805 $2.0923 $2.29781
Non-recurring
Other operating expenses
Total operating expenses
Operating income -$8.181735 -$8.243875 -$7.970808 -$8.35827
Income from continuing operations
Net other income $0.231634 $0.102079 $0.039495 $0.029673
EBIT -$7.950101 -$8.141796 -$7.931313 -$8.328597
Interest expense
Income before tax -$7.950101 -$8.141796 -$7.931313 -$8.328597
Income tax expense
Minority interest
Net income from continuing ops -$7.950101 -$8.141796 -$7.931313 -$8.328597
Non-recurring events
Discontinued operations
Extraordinary items
Effect of accounting change
Other items
Net income
EBITDA -$7.950101 -$8.141796 -$7.931313 -$8.328597
Income (for common shares) -$7.950101 -$8.141796 -$7.931313 -$8.328597
(in millions) 2016 2015 2014
Revenue
Total revenue $0.0185 $20.07075 $15.027004
Cost of revenue
Gross profit $0.0185 $20.07075 $15.027004
Operating expenses
Research & development $23.28182 $25.050179 $19.571073
Selling, general & administrative $8.650165 $7.805396 $6.595738
Non-recurring
Other operating expenses
Total operating expenses
Operating income -$31.913485 -$12.784825 -$11.139807
Income from continuing operations
Net other income $0.103647 $0.015327 $0.018241
EBIT -$31.809838 -$12.769498 -$11.121566
Interest expense
Income before tax -$31.809838 -$12.769498 -$11.121566
Income tax expense
Minority interest
Net income from continuing ops -$31.809838 -$12.769498 -$11.121566
Non-recurring events
Discontinued operations
Extraordinary items
Effect of accounting change
Other items
Net income
EBITDA -$31.809838 -$12.769498 -$11.121566
Income (for common shares) -$31.809838 -$12.769498 -$11.121566

Cash flow

(in millions) 2017Q3 2017Q2 2017Q1 2016Q4
Net income -$7.950101 -$8.141796 -$7.931313 -$8.328597
Operating activities
Depreciation $0.07006 $0.069577 $0.054339 $0.050791
Net income adjustments $0.962346 $0.991108 $0.842847 $0.72612
Change in accounts receivable
Changes in liabilities $1.213533 $0.78968 -$1.811451 $0.93655
Changes in inventory
Changes in other operating activities -$0.525716 $0.183437 -$0.216037 $0.660519
Total cash flow from operations -$6.229878 -$6.107994 -$9.061615 -$5.954617
Investing activities
Capital expenditures -$0.032687 -$0.164204 -$0.062969 -$0.438567
Investments
Other cash flows from investing
Total cash flows from investing -$0.032687 -$0.164204 -$0.062969 -$0.438567
Financing activities
Dividends paid
Sale and purchase of stock -$0.012829 $90.829548 $3.673521 $1.152275
Net borrowings
Other cash flows from financing
Total cash flows from financing -$0.012829 $90.829548 $3.673521 $1.152275
Effect of exchange rate
Change in cash and equivalents -$6.275394 $84.55735 -$5.451063 -$5.240909
(in millions) 2016 2015 2014
Net income -$31.809838 -$12.769498 -$11.121566
Operating activities
Depreciation $0.19054 $0.191484 $0.158708
Net income adjustments $2.964767 $2.331604 $1.636489
Change in accounts receivable
Changes in liabilities -$1.503204 $1.383446 $4.188425
Changes in inventory
Changes in other operating activities $0.42647 $0.621074 $0.856357
Total cash flow from operations -$29.731265 -$8.24189 -$4.281587
Investing activities
Capital expenditures -$0.704202 -$0.268594 -$0.212603
Investments
Other cash flows from investing
Total cash flows from investing -$0.704202 -$0.268594 -$0.212603
Financing activities
Dividends paid
Sale and purchase of stock $23.674548 $0.114121 $57.38251
Net borrowings
Other cash flows from financing
Total cash flows from financing $23.674548 $0.114121 $57.38251
Effect of exchange rate
Change in cash and equivalents -$6.760919 -$8.396363 $52.88832
Messenger